Copyright Reports & Markets. All rights reserved.

Global Myotonic Muscular Dystrophy (DMD) Treatments Key Trends and Opportunities to 2027

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Market Analysis by Type
    • 1.2.1 Global Myotonic Muscular Dystrophy (DMD) Treatments Market Size by Type: 2016 VS 2021 VS 2027
    • 1.2.2 Medications
    • 1.2.3 Rehabilitative Therapies
    • 1.2.4 Devices
    • 1.2.5 Surgeries
  • 1.3 Market by Application
    • 1.3.1 Global Myotonic Muscular Dystrophy (DMD) Treatments Market Share by Application: 2016 VS 2021 VS 2027
    • 1.3.2 Hospitals
    • 1.3.3 Specialty Clinics
    • 1.3.4 Ambulatory Surgery Centers
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Global Growth Trend

  • 2.1 Global Myotonic Muscular Dystrophy (DMD) Treatments Market Perspective (2016-2027)
  • 2.2 Global Myotonic Muscular Dystrophy (DMD) Treatments Growth Trends by Regions
    • 2.2.1 Myotonic Muscular Dystrophy (DMD) Treatments Market Size by Regions: 2016 VS 2021 VS 2027
    • 2.2.2 Myotonic Muscular Dystrophy (DMD) Treatments Historic Market Size by Regions (2016-2021)
    • 2.2.3 Myotonic Muscular Dystrophy (DMD) Treatments Forecasted Market Size by Regions (2022-2027)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Myotonic Muscular Dystrophy (DMD) Treatments Industry Trends
    • 2.3.2 Myotonic Muscular Dystrophy (DMD) Treatments Market Drivers
    • 2.3.3 Myotonic Muscular Dystrophy (DMD) Treatments Market Challenges
    • 2.3.4 Myotonic Muscular Dystrophy (DMD) Treatments Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top Myotonic Muscular Dystrophy (DMD) Treatments Players by Market Size
    • 3.1.1 Players Covered: Ranking by Myotonic Muscular Dystrophy (DMD) Treatments Revenue
    • 3.1.2 Global Top Myotonic Muscular Dystrophy (DMD) Treatments Players by Revenue (2016-2021)
    • 3.1.3 Global Myotonic Muscular Dystrophy (DMD) Treatments Revenue Market Share by Players (2016-2021)
    • 3.1.4 Global Myotonic Muscular Dystrophy (DMD) Treatments Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.2 Global Myotonic Muscular Dystrophy (DMD) Treatments Market Concentration Ratio
    • 3.2.1 Global Myotonic Muscular Dystrophy (DMD) Treatments Market Concentration Ratio (CR5 and HHI)
    • 3.2.2 Global Top 5 and Top 10 Players by Myotonic Muscular Dystrophy (DMD) Treatments Revenue in 2020
  • 3.3 Myotonic Muscular Dystrophy (DMD) Treatments Key Players Head office and Area Served
  • 3.4 Key Players Myotonic Muscular Dystrophy (DMD) Treatments Product Solution and Service
  • 3.5 Date of Enter into Myotonic Muscular Dystrophy (DMD) Treatments Market
  • 3.6 Mergers & Acquisitions, Expansion Plans

4 Global Myotonic Muscular Dystrophy (DMD) Treatments Breakdown Data by Type (2016-2027)

  • 4.1 Global Myotonic Muscular Dystrophy (DMD) Treatments Historic Market Size by Type (2016-2021)
  • 4.2 Global Myotonic Muscular Dystrophy (DMD) Treatments Forecasted Market Size by Type (2022-2027)

5 Global Myotonic Muscular Dystrophy (DMD) Treatments Breakdown Data by Application (2016-2027)

  • 5.1 Global Myotonic Muscular Dystrophy (DMD) Treatments Historic Market Size by Application (2016-2021)
  • 5.2 Myotonic Muscular Dystrophy (DMD) Treatments Forecasted Market Size by Application (2022-2027)

6 North America

  • 6.1 North America Myotonic Muscular Dystrophy (DMD) Treatments Market Size (2016-2027)
  • 6.2 Key Myotonic Muscular Dystrophy (DMD) Treatments Players Market Share in North America (2020-2021)
  • 6.3 North America Myotonic Muscular Dystrophy (DMD) Treatments Market Size by Country
    • 6.3.1 North America Myotonic Muscular Dystrophy (DMD) Treatments Sales by Country (2016-2021)
    • 6.3.2 North America Myotonic Muscular Dystrophy (DMD) Treatments Market Size Forecast by Country (2022-2027)
  • 6.4 U.S. Market Size Analysis
    • 6.4.1 U.S. Myotonic Muscular Dystrophy (DMD) Treatments Market Size (2016-2027)
    • 6.4.2 U.S. Myotonic Muscular Dystrophy (DMD) Treatments Market Size by Type (2016-2027)
    • 6.4.3 U.S. Myotonic Muscular Dystrophy (DMD) Treatments Market Size by Application (2016-2027)
  • 6.5 Canada Market Size Analysis
    • 6.5.1 Canada Myotonic Muscular Dystrophy (DMD) Treatments Market Size (2016-2027)
    • 6.5.2 Canada Myotonic Muscular Dystrophy (DMD) Treatments Market Size by Type (2016-2027)
    • 6.5.3 Canada Myotonic Muscular Dystrophy (DMD) Treatments Market Size by Application (2016-2027)

7 Europe

  • 7.1 Europe Myotonic Muscular Dystrophy (DMD) Treatments Market Size (2016-2027)
  • 7.2 Key Myotonic Muscular Dystrophy (DMD) Treatments Players Market Share in Europe (2020-2021)
  • 7.3 Europe Myotonic Muscular Dystrophy (DMD) Treatments Market Size by Country
    • 7.3.1 Europe Myotonic Muscular Dystrophy (DMD) Treatments Sales by Country (2016-2021)
    • 7.3.2 Europe Myotonic Muscular Dystrophy (DMD) Treatments Market Size Forecast by Country (2022-2027)
  • 7.4 Germany Market Size Analysis
    • 7.4.1 Germany Myotonic Muscular Dystrophy (DMD) Treatments Market Size (2016-2027)
    • 7.4.2 Germany Myotonic Muscular Dystrophy (DMD) Treatments Market Size by Type (2016-2027)
    • 7.4.3 Germany Myotonic Muscular Dystrophy (DMD) Treatments Market Size by Application (2016-2027)
  • 7.5 France Market Size Analysis
    • 7.5.1 France Myotonic Muscular Dystrophy (DMD) Treatments Market Size (2016-2027)
    • 7.5.2 France Myotonic Muscular Dystrophy (DMD) Treatments Market Size by Type (2016-2027)
    • 7.5.3 France Myotonic Muscular Dystrophy (DMD) Treatments Market Size by Application (2016-2027)
  • 7.6 U.K. Market Size Analysis
    • 7.6.1 U.K. Myotonic Muscular Dystrophy (DMD) Treatments Market Size (2016-2027)
    • 7.6.2 U.K. Myotonic Muscular Dystrophy (DMD) Treatments Market Size by Type (2016-2027)
    • 7.6.3 U.K. Myotonic Muscular Dystrophy (DMD) Treatments Market Size by Application (2016-2027)
  • 7.7 Italy Market Size Analysis
    • 7.7.1 Italy Myotonic Muscular Dystrophy (DMD) Treatments Market Size (2016-2027)
    • 7.7.2 Italy Myotonic Muscular Dystrophy (DMD) Treatments Market Size by Type (2016-2027)
    • 7.7.3 Italy Myotonic Muscular Dystrophy (DMD) Treatments Market Size by Application (2016-2027)
  • 7.8 Russia Market Size Analysis
    • 7.8.1 Russia Myotonic Muscular Dystrophy (DMD) Treatments Market Size (2016-2027)
    • 7.8.2 Russia Myotonic Muscular Dystrophy (DMD) Treatments Market Size by Type (2016-2027)
    • 7.8.3 Russia Myotonic Muscular Dystrophy (DMD) Treatments Market Size by Application (2016-2027)

8 Asia-Pacific

  • 8.1 Asia-Pacific Myotonic Muscular Dystrophy (DMD) Treatments Market Size (2016-2027)
  • 8.2 Key Myotonic Muscular Dystrophy (DMD) Treatments Players Market Share in Asia-Pacific (2020-2021)
  • 8.3 Asia-Pacific Myotonic Muscular Dystrophy (DMD) Treatments Market Size by Region
    • 8.3.1 Asia-Pacific Myotonic Muscular Dystrophy (DMD) Treatments Sales by Region (2016-2021)
    • 8.3.2 Asia-Pacific Myotonic Muscular Dystrophy (DMD) Treatments Market Size Forecast by Region (2022-2027)
  • 8.4 China Market Size Analysis
    • 8.4.1 China Myotonic Muscular Dystrophy (DMD) Treatments Market Size (2016-2027)
    • 8.4.2 China Myotonic Muscular Dystrophy (DMD) Treatments Market Size by Type (2016-2027)
    • 8.4.3 China Myotonic Muscular Dystrophy (DMD) Treatments Market Size by Application (2016-2027)
  • 8.5 Japan Market Size Analysis
    • 8.5.1 Japan Myotonic Muscular Dystrophy (DMD) Treatments Market Size (2016-2027)
    • 8.5.2 Japan Myotonic Muscular Dystrophy (DMD) Treatments Market Size by Type (2016-2027)
    • 8.5.3 Japan Myotonic Muscular Dystrophy (DMD) Treatments Market Size by Application (2016-2027)
  • 8.6 South Korea Market Size Analysis
    • 8.6.1 South Korea Myotonic Muscular Dystrophy (DMD) Treatments Market Size (2016-2027)
    • 8.6.2 South Korea Myotonic Muscular Dystrophy (DMD) Treatments Market Size by Type (2016-2027)
    • 8.6.3 South Korea Myotonic Muscular Dystrophy (DMD) Treatments Market Size by Application (2016-2027)
  • 8.7 India Market Size Analysis
    • 8.7.1 India Myotonic Muscular Dystrophy (DMD) Treatments Market Size (2016-2027)
    • 8.7.2 India Myotonic Muscular Dystrophy (DMD) Treatments Market Size by Type (2016-2027)
    • 8.7.3 India Myotonic Muscular Dystrophy (DMD) Treatments Market Size by Application (2016-2027)
  • 8.8 Australia Market Size Analysis
    • 8.8.1 Australia Myotonic Muscular Dystrophy (DMD) Treatments Market Size (2016-2027)
    • 8.8.2 Australia Myotonic Muscular Dystrophy (DMD) Treatments Market Size by Type (2016-2027)
    • 8.8.3 Australia Myotonic Muscular Dystrophy (DMD) Treatments Market Size by Application (2016-2027)
  • 8.9 Taiwan Market Size Analysis
    • 8.9.1 Taiwan Myotonic Muscular Dystrophy (DMD) Treatments Market Size (2016-2027)
    • 8.9.2 Taiwan Myotonic Muscular Dystrophy (DMD) Treatments Market Size by Type (2016-2027)
    • 8.9.3 Taiwan Myotonic Muscular Dystrophy (DMD) Treatments Market Size by Application (2016-2027)
  • 8.10 Indonesia Market Size Analysis
    • 8.10.1 Indonesia Myotonic Muscular Dystrophy (DMD) Treatments Market Size (2016-2027)
    • 8.10.2 Indonesia Myotonic Muscular Dystrophy (DMD) Treatments Market Size by Type (2016-2027)
    • 8.10.3 Indonesia Myotonic Muscular Dystrophy (DMD) Treatments Market Size by Application (2016-2027)
  • 8.11 Thailand Market Size Analysis
    • 8.11.1 Thailand Myotonic Muscular Dystrophy (DMD) Treatments Market Size (2016-2027)
    • 8.11.2 Thailand Myotonic Muscular Dystrophy (DMD) Treatments Market Size by Type (2016-2027)
    • 8.11.3 Thailand Myotonic Muscular Dystrophy (DMD) Treatments Market Size by Application (2016-2027)
  • 8.12 Malaysia Market Size Analysis
    • 8.12.1 Malaysia Myotonic Muscular Dystrophy (DMD) Treatments Market Size (2016-2027)
    • 8.12.2 Malaysia Myotonic Muscular Dystrophy (DMD) Treatments Market Size by Type (2016-2027)
    • 8.12.3 Malaysia Myotonic Muscular Dystrophy (DMD) Treatments Market Size by Application (2016-2027)
  • 8.13 Philippines Market Size Analysis
    • 8.13.1 Philippines Myotonic Muscular Dystrophy (DMD) Treatments Market Size (2016-2027)
    • 8.13.2 Philippines Myotonic Muscular Dystrophy (DMD) Treatments Market Size by Type (2016-2027)
    • 8.13.3 Philippines Myotonic Muscular Dystrophy (DMD) Treatments Market Size by Application (2016-2027)
  • 8.14 Vietnam Market Size Analysis
    • 8.14.1 Vietnam Myotonic Muscular Dystrophy (DMD) Treatments Market Size (2016-2027)
    • 8.14.2 Vietnam Myotonic Muscular Dystrophy (DMD) Treatments Market Size by Type (2016-2027)
    • 8.14.3 Vietnam Myotonic Muscular Dystrophy (DMD) Treatments Market Size by Application (2016-2027)

9 Latin America

  • 9.1 Latin America Myotonic Muscular Dystrophy (DMD) Treatments Market Size (2016-2027)
  • 9.2 Key Myotonic Muscular Dystrophy (DMD) Treatments Players Market Share in Latin America (2020-2021)
  • 9.3 Latin America Myotonic Muscular Dystrophy (DMD) Treatments Market Size by Country
    • 9.3.1 Latin America Myotonic Muscular Dystrophy (DMD) Treatments Sales by Country (2016-2021)
    • 9.3.2 Latin America Myotonic Muscular Dystrophy (DMD) Treatments Market Size Forecast by Country (2022-2027)
  • 9.4 Mexico Market Size Analysis
    • 9.4.1 Mexico Myotonic Muscular Dystrophy (DMD) Treatments Market Size (2016-2027)
    • 9.4.2 Mexico Myotonic Muscular Dystrophy (DMD) Treatments Market Size by Type (2016-2027)
    • 9.4.3 Mexico Myotonic Muscular Dystrophy (DMD) Treatments Market Size by Application (2016-2027)
  • 9.5 Brazil Market Size Analysis
    • 9.5.1 Brazil Myotonic Muscular Dystrophy (DMD) Treatments Market Size (2016-2027)
    • 9.5.2 Brazil Myotonic Muscular Dystrophy (DMD) Treatments Market Size by Type (2016-2027)
    • 9.5.3 Brazil Myotonic Muscular Dystrophy (DMD) Treatments Market Size by Application (2016-2027)
  • 9.6 Argentina Market Size Analysis
    • 9.6.1 Argentina Myotonic Muscular Dystrophy (DMD) Treatments Market Size (2016-2027)
    • 9.6.2 Argentina Myotonic Muscular Dystrophy (DMD) Treatments Market Size by Type (2016-2027)
    • 9.6.3 Argentina Myotonic Muscular Dystrophy (DMD) Treatments Market Size by Application (2016-2027)

10 Middle East & Africa

  • 10.1 Middle East & Africa Myotonic Muscular Dystrophy (DMD) Treatments Market Size (2016-2027)
  • 10.2 Key Myotonic Muscular Dystrophy (DMD) Treatments Players Market Share in Middle East & Africa (2020-2021)
  • 10.3 Middle East & Africa Myotonic Muscular Dystrophy (DMD) Treatments Market Size by Country
    • 10.3.1 Middle East & Africa Myotonic Muscular Dystrophy (DMD) Treatments Sales by Country (2016-2021)
    • 10.3.2 Middle East & Africa Myotonic Muscular Dystrophy (DMD) Treatments Market Size Forecast by Country (2022-2027)
  • 10.4 Turkey Market Size Analysis
    • 10.4.1 Turkey Myotonic Muscular Dystrophy (DMD) Treatments Market Size (2016-2027)
    • 10.4.2 Turkey Myotonic Muscular Dystrophy (DMD) Treatments Market Size by Type (2016-2027)
    • 10.4.3 Turkey Myotonic Muscular Dystrophy (DMD) Treatments Market Size by Application (2016-2027)
  • 10.5 Saudi Arabia Market Size Analysis
    • 10.5.1 Saudi Arabia Myotonic Muscular Dystrophy (DMD) Treatments Market Size (2016-2027)
    • 10.5.2 Saudi Arabia Myotonic Muscular Dystrophy (DMD) Treatments Market Size by Type (2016-2027)
    • 10.5.3 Saudi Arabia Myotonic Muscular Dystrophy (DMD) Treatments Market Size by Application (2016-2027)
  • 10.6 UAE Market Size Analysis
    • 10.6.1 UAE Myotonic Muscular Dystrophy (DMD) Treatments Market Size (2016-2027)
    • 10.6.2 UAE Myotonic Muscular Dystrophy (DMD) Treatments Market Size by Type (2016-2027)
    • 10.6.3 UAE Myotonic Muscular Dystrophy (DMD) Treatments Market Size by Application (2016-2027)

11 Key Players Profiles

  • 11.1 Pfizer, Inc.
    • 11.1.1 Pfizer, Inc. Company Details
    • 11.1.2 Pfizer, Inc. Business Overview and Its Total Revenue
    • 11.1.3 Pfizer, Inc. Myotonic Muscular Dystrophy (DMD) Treatments Introduction
    • 11.1.4 Pfizer, Inc. Revenue in Myotonic Muscular Dystrophy (DMD) Treatments Business (2016-2021)
    • 11.1.5 Pfizer, Inc. Recent Development
  • 11.2 Eli Lilly and Company
    • 11.2.1 Eli Lilly and Company Company Details
    • 11.2.2 Eli Lilly and Company Business Overview and Its Total Revenue
    • 11.2.3 Eli Lilly and Company Myotonic Muscular Dystrophy (DMD) Treatments Introduction
    • 11.2.4 Eli Lilly and Company Revenue in Myotonic Muscular Dystrophy (DMD) Treatments Business (2016-2021)
    • 11.2.5 Eli Lilly and Company Recent Development
  • 11.3 Mylan Pharmaceuticals Inc.
    • 11.3.1 Mylan Pharmaceuticals Inc. Company Details
    • 11.3.2 Mylan Pharmaceuticals Inc. Business Overview and Its Total Revenue
    • 11.3.3 Mylan Pharmaceuticals Inc. Myotonic Muscular Dystrophy (DMD) Treatments Introduction
    • 11.3.4 Mylan Pharmaceuticals Inc. Revenue in Myotonic Muscular Dystrophy (DMD) Treatments Business (2016-2021)
    • 11.3.5 Mylan Pharmaceuticals Inc. Recent Development
  • 11.4 Wockhardt Ltd.
    • 11.4.1 Wockhardt Ltd. Company Details
    • 11.4.2 Wockhardt Ltd. Business Overview and Its Total Revenue
    • 11.4.3 Wockhardt Ltd. Myotonic Muscular Dystrophy (DMD) Treatments Introduction
    • 11.4.4 Wockhardt Ltd. Revenue in Myotonic Muscular Dystrophy (DMD) Treatments Business (2016-2021)
    • 11.4.5 Wockhardt Ltd. Recent Development
  • 11.5 Teva Pharmaceutical Industries Ltd.
    • 11.5.1 Teva Pharmaceutical Industries Ltd. Company Details
    • 11.5.2 Teva Pharmaceutical Industries Ltd. Business Overview and Its Total Revenue
    • 11.5.3 Teva Pharmaceutical Industries Ltd. Myotonic Muscular Dystrophy (DMD) Treatments Introduction
    • 11.5.4 Teva Pharmaceutical Industries Ltd. Revenue in Myotonic Muscular Dystrophy (DMD) Treatments Business (2016-2021)
    • 11.5.5 Teva Pharmaceutical Industries Ltd. Recent Development
  • 11.6 Novartis AG
    • 11.6.1 Novartis AG Company Details
    • 11.6.2 Novartis AG Business Overview and Its Total Revenue
    • 11.6.3 Novartis AG Myotonic Muscular Dystrophy (DMD) Treatments Introduction
    • 11.6.4 Novartis AG Revenue in Myotonic Muscular Dystrophy (DMD) Treatments Business (2016-2021)
    • 11.6.5 Novartis AG Recent Development
  • 11.7 BioMarin Pharmaceutical, Inc.
    • 11.7.1 BioMarin Pharmaceutical, Inc. Company Details
    • 11.7.2 BioMarin Pharmaceutical, Inc. Business Overview and Its Total Revenue
    • 11.7.3 BioMarin Pharmaceutical, Inc. Myotonic Muscular Dystrophy (DMD) Treatments Introduction
    • 11.7.4 BioMarin Pharmaceutical, Inc. Revenue in Myotonic Muscular Dystrophy (DMD) Treatments Business (2016-2021)
    • 11.7.5 BioMarin Pharmaceutical, Inc. Recent Development
  • 11.8 Asklepios Kliniken GmbH
    • 11.8.1 Asklepios Kliniken GmbH Company Details
    • 11.8.2 Asklepios Kliniken GmbH Business Overview and Its Total Revenue
    • 11.8.3 Asklepios Kliniken GmbH Myotonic Muscular Dystrophy (DMD) Treatments Introduction
    • 11.8.4 Asklepios Kliniken GmbH Revenue in Myotonic Muscular Dystrophy (DMD) Treatments Business (2016-2021)
    • 11.8.5 Asklepios Kliniken GmbH Recent Development
  • 11.9 Hoveround Corporation
    • 11.9.1 Hoveround Corporation Company Details
    • 11.9.2 Hoveround Corporation Business Overview and Its Total Revenue
    • 11.9.3 Hoveround Corporation Myotonic Muscular Dystrophy (DMD) Treatments Introduction
    • 11.9.4 Hoveround Corporation Revenue in Myotonic Muscular Dystrophy (DMD) Treatments Business (2016-2021)
    • 11.9.5 Hoveround Corporation Recent Development
  • 11.10 Siemens Healthcare
    • 11.10.1 Siemens Healthcare Company Details
    • 11.10.2 Siemens Healthcare Business Overview and Its Total Revenue
    • 11.10.3 Siemens Healthcare Myotonic Muscular Dystrophy (DMD) Treatments Introduction
    • 11.10.4 Siemens Healthcare Revenue in Myotonic Muscular Dystrophy (DMD) Treatments Business (2016-2021)
    • 11.10.5 Siemens Healthcare Recent Development

12 Analyst's Viewpoints/Conclusion

    13 Appendix

    • 13.1 Research Methodology
      • 13.1.1 Methodology/Research Approach
      • 13.1.2 Data Source

    Myotonic Muscular Dystrophy (DMD) Treatments market is segmented by companies, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Myotonic Muscular Dystrophy (DMD) Treatments market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on market size and forecast for the period 2016-2027.
    Segment by Type, the Myotonic Muscular Dystrophy (DMD) Treatments market is segmented into Medications, Rehabilitative Therapies, Devices, Surgeries, etc.
    Segment by Application, the Myotonic Muscular Dystrophy (DMD) Treatments market is segmented into Hospitals, Specialty Clinics, Ambulatory Surgery Centers, etc.

    Regional and Country-level Analysis
    The report offers exhaustive assessment of different region-wise and country-wise Myotonic Muscular Dystrophy (DMD) Treatments markets such as the U.S., Canada, Germany, France, the U.K., Italy, Russia, China, Japan, South Korea, Taiwan, India, Australia, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Argentina, Saudi Arabia, UAE, Turkey, etc.
    The report includes country-wise and region-wise market size for the period 2016-2027, by countries (regions), by Type, and by Application, as well as by players for North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.

    Competitive Landscape and Myotonic Muscular Dystrophy (DMD) Treatments Market Share Analysis
    Myotonic Muscular Dystrophy (DMD) Treatments market competitive landscape provides details and data information by vendors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2016-2021. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2016-2021. Details included are company description, major business, company total revenue and revenue generated in Myotonic Muscular Dystrophy (DMD) Treatments business, the date to enter into the Myotonic Muscular Dystrophy (DMD) Treatments market, Myotonic Muscular Dystrophy (DMD) Treatments product introduction, recent developments, etc.
    The major vendors include Pfizer, Inc., Eli Lilly and Company, Mylan Pharmaceuticals Inc., Wockhardt Ltd., Teva Pharmaceutical Industries Ltd., Novartis AG, BioMarin Pharmaceutical, Inc., Asklepios Kliniken GmbH, Hoveround Corporation, Siemens Healthcare, etc.

    Buy now